Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population (EMPACT): A Randomized Controlled Trial

NCT06096909 is registered in ClinicalTrials.gov with China National Center for Cardiovascular Diseases as lead sponsor.

NCT NCT06096909
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06096909 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population (EMPACT): A Randomized Controlled Trial
Lead sponsor
China National Center for Cardiovascular Diseases
Phase
Not applicable
Overall status
Not yet recruiting
Start date
November 1, 2023
Completion date
November 1, 2027
Enrollment
3,684 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute coronary syndrome, non st segment elevation acute coronary syndrome